AC IMMUNE

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 30 Sept 2019 filing date already counts against anyone who files later.

Record

Serial number

88636116

Mark type

Design + words

Filed

30 Sept 2019

Published for opposition

13 May 2025

Attorney of record

Kristina Montanaro Schrader

Goods and services

• Class 001 — Chemicals: Chemicals for use in industry and science; chemical substances, chemical materials and chemical preparations, and natural elements, namely, chemical preparations for industrial and scientific purposes, other than for medical or veterinary use; chemical, biochemical, biological and biotechnological preparations for use in industry and science; protein, protein fragments, amino acids, antibodies and fragments thereof for industrial, scientific or research purposes, other than for medical or veterinary use; chemical preparations comprising small molecules for use in industry and science; molecular libraries, comprising libraries of chemical preparations for use in industry and science; small molecule library, comprising libraries of chemical preparations for use in industry and science; antibody library, comprising libraries of antibodies for scientific or research use; reagents for use in the development of antibodies, proteins for binding or detecting antibodies and antibody-producing hybridoma cells for scientific or research purposes or for industrial use; detectably labelled compound for industrial, scientific purposes; diagnostic reagents for industrial, scientific or research purposes; immunological reagents for industrial, scientific or research purposes; biological cell, biological tissue culture for use in non-medical research laboratories; diagnostic tools in the nature of preparations, companion diagnostic agents, biomarkers, imaging agents, PET-Imaging compounds for industrial, scientific purposes other than for medical or veterinary use; diagnostic reagents for industrial, scientific or research purposes other than for medical or veterinary use; none of the aforesaid goods relating to development of pharmaceutical therapies to prevent, manage, and treat food related, gastrointestinal, allergic and inborn error of metabolism diseases
• Class 005 — Pharmaceuticals: Pharmaceuticals, medical and veterinary preparations for the diagnosis, prevention and treatment of neurodegenerative diseases and inflammatory diseases; diagnostic preparations and materials for medical or veterinary purposes; companion diagnostic agents, biomarkers, imaging agents, PET-Imaging compounds, all for medical purposes; chemical preparations for medical purposes, namely, for the diagnosis, prevention and treatment of neurodegenerative diseases and inflammatory diseases; chemico-pharmaceutical preparation for medical purposes, namely, for the diagnosis, prevention and treatment of neurodegenerative diseases and inflammatory diseases; antibodies, antibody fragments and antibody derivatives for use in disease testing, diagnosis, prevention and treatment for medical purposes; pharmaceutical and medical preparations in the nature of small molecule compounds for medical purposes; PET-Imaging compounds in the nature of diagnostic radiopharmaceutical agents for use in PET imaging; diagnostic preparations in the nature of companion compounds for medical use; pharmaceutical and medical preparations in the nature of biomarkers for medical purposes; vaccines; antigenic peptides for the diagnosis, prevention and treatment of neurodegenerative diseases and inflammatory diseases; pharmaceutical and medical preparations in the nature of protein or protein fragments for medical purposes; diagnostic reagents for medical purposes; diagnostic antibodies for medical purposes; none of the aforesaid goods relating to development of pharmaceutical therapies to prevent, manage, and treat food related, gastrointestinal, allergic and inborn error of metabolism diseases
• Class 042 — Scientific and technological services: Scientific and technological services, namely, scientific research, analysis and testing and the development of technology in the field of medicine and pharmaceuticals and research activities relating thereto; providing access to a proprietary technology platform containing antibodies, vaccines and small molecules that gives users the ability to obtain information for research purposes; biological research services; chemical research services in the fields of neurodegenerative diseases and inflammatory diseases; medical research services; scientific and medical laboratory services in biotechnology, chemistry, pharmacy, molecular science and immunotherapy; providing medical and scientific research information in the field of biotechnology, chemistry, pharmacy, molecular science, immunotherapy, therapeutics, diagnostics and clinical trials; scientific research, development and consultancy in the field of biotechnology, chemistry, pharmacy, molecular science, immunotherapy, therapeutics, diagnostics and clinical trials; development of test procedures, assays, test reagents, PET-imaging, companion diagnostic biomarkers, antibodies, vaccines and test kits for the field of biotechnology, chemistry, pharmacy, molecular science, immunotherapy, therapeutics, diagnostics and clinical trials; biological research, namely, screening and selection of pharmaceutical active substances from biological and biotechnological preparations; custom design and development of biological assays; research and development, namely, vaccine and antibody engineering; none of the aforesaid services relating to development of pharmaceutical therapies to prevent, manage, and treat food related, gastrointestinal, allergic and inborn error of metabolism diseases

Owner

• AC Immune SA, Lausanne, CH
• AC Immune SA, Lausanne, CH

Prosecution history

• 29 Dec 2025 — TEAS DELETE 1(B) BASIS RECEIVED
• 08 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 13 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 13 May 2025 — PUBLISHED FOR OPPOSITION
• 07 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 17 Apr 2025 — ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
• 08 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 07 Apr 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 07 Apr 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 07 Apr 2025 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
• 06 Jan 2025 — NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
• 06 Jan 2025 — INQUIRY TO SUSPENSION E-MAILED
• 06 Jan 2025 — SUSPENSION INQUIRY WRITTEN
• 23 Dec 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 23 Dec 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE